Data on an investigational drug for treating a form of skin cancer indicate it is highly active when combined with a commonly used immunotherapy drug, according to a presentation over the weekend at the American Society of Clinical Oncology meeting in Chicago.
San Francisco-based Nektar Therapeutics showed data Saturday from its Phase II PIVOT-02 study of bempegaldesleukin with Bristol-Myers Squibb’s PD-1 checkpoint inhibitor Opdivo (nivolumab) in first-line, Stage III-IV metastatic melanoma. Bempegaldesleukin, also known as bempeg for short, is an IL-2 pathway agonist preferential to the antigen CD122.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Among 38 patients from the study, the overall response rate was 53 percent after a median 12.7-month followup, including a 34 percent complete response rate. Mild to moderate side effects occurring in more than 30 percent of 41 patients included fatigue, pyrexia, rash, pruritus, nausea, influenza-like illness, arthralgia, chills and myalgia. Serious or worse side effects occurred in less than 15 percent of patients, with 9.8 percent of patients discontinuing treatment due to treatment-related side effects.
Shares of Nektar were up 13 percent on the Nasdaq Monday morning following the news.
Bempeg is currently undergoing a Phase III trial, comparing the two-drug combination against Opdivo alone. If that trial can show results equivalent or better than a combination of Opdivo with another BMS immunotherapy drug, the CTLA-4 inhibitor Yervoy (ipilimumab), then bempeg and Opdivo will become widely used, wrote Dr. Adi Diab, a melanoma specialist at The University of Texas MD Anderson Cancer Center and PIVOT-2 investigator, in an email. “Given that bempeg plus [Opdivo] is well-tolerated, and coupled with the high CR rate, this doublet could easily become the first-line standard of care of melanoma,” Diab wrote. That would allow for Yervoy to be used in second-line treatment instead, he wrote, adding that most melanoma patients are treated with single-agent PD-1 inhibitors. In addition to Opdivo, Merck & Co.’s Keytruda (pembrolizumab) also has Food and Drug Administration approval for melanoma.
Whether overall response rate data from a few dozen patients with melanoma can be extrapolated to a randomized Phase III trial of 764 patients, only time will tell. The trial is using overall response rate, progression-free survival and overall survival as co-primary endpoints. Diab wrote that as a two-arm study, the Phase III bempeg and Opdivo trial is appropriately powered with the 764-patient enrollment target.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
For comparison’s sake, according to four-year follow-up data published in The Lancet in October 2018 on CheckMate 067 – a three-arm, 1,296-patient Phase III trial in a similar melanoma population that tested Opdivo and Yervoy against Opdivo or Yervoy alone – the overall response rate for the combination was 58 percent, similar to the one in PIVOT-2. However, the complete response rate was 21 percent for Opdivo with Yervoy, 18 percent for Opdivo alone and 5 percent for Yervoy alone. Median overall survival for the two-drug combination was not reached, while for the two drugs by themselves it was 36.9 months and 19.9 months, respectively. Median progression-free survival was 11.5 months for Opdivo with Yervoy, 6.9 months for Opdivo and 2.9 months for Yervoy.
Photo: Alaric DeArment, MedCity News
